Does Moderna’s RSV vaccine lose efficacy faster than others?
Follow-up data from Moderna’s Phase 3 RSV vaccine trial reveals that its efficacy dwindles faster than vaccines made by GSK and Pfizer. The vaccine saw a 25% decline in efficacy…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Our podcast this week centers exclusively on a tantalizing subject: Artificial intelligence in biotech. Give it a listen. Also, Moderna’s RSV vaccine efficacy seems lackluster compared to competitors, and the Bernie Sanders drug pricing song-and-dance did not seem to faze pharma CEOs.
What's Your Reaction?
